Rikuta Hamaya1,2, Samia Mora1,3, Patrick R Lawler4, Nancy R Cook1,5, Paul M Ridker1, Julie E Buring1,6,5, I-Min Lee5, JoAnn E Manson5, Deirdre K Tobias1,2. 1. Division of Preventive Medicine, Department of Medicine (R.H., S.M., N.R.C., P.M.R., J.E.B., I.L., J.E.M., D.K.T.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2. Department of Nutrition (R.H., D.K.T.), Harvard T.H. 3. Center for Lipid Metabolomics, Division of Cardiovascular Medicine (S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Chan School of Public Health, Boston, MA. Peter Munk Cardiac Centre, University Health Network, and Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, ON, Canada (P.R.L.). 5. Department of Epidemiology (N.R.C., J.E.B., I.L., J.E.M.), Harvard T.H. 6. Mary Horrigan Connors Center for Women's Health and Gender Biology (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) correlate with insulin resistance and poor glucose control, which may in part explain associations between type 2 diabetes and cardiovascular disease. However, the relationships of BCAAs with other cardiometabolic pathways, including inflammation and dyslipidemia, are unclear. We hypothesized that plasma BCAAs would correlate with multiple pathways of cardiometabolic dysfunction. METHODS: We conducted a cross-sectional analysis among 19 472 participants (mean age=54.9 years, SD=7.2 years) in the Women's Health Study without a history of type 2 diabetes, cardiovascular disease, or cancer. We quantified the concentrations of individual biomarkers of inflammation and lipids, across quartiles of BCAAs, adjusting for age, smoking, body mass index, physical activity, and other established cardiovascular disease risk factors at blood draw. RESULTS: Women in the highest versus lowest quartiles of plasma BCAAs had higher inflammatory markers including high-sensitivity C-reactive protein (multivariable-adjusted means: 1.96 versus 1.43 mg/L), fibrinogen (367 versus 362 mg/dL), soluble intercellular cell adhesion molecule-1 (361 versus 353 ng/mL), and glycoprotein acetylation (407 versus 371 µmol/L; P trend=0.0002 for fibrinogen; P<0.0001 for others). Similarly for lipids, women with higher BCAAs had lower HDL-C (high-density lipoprotein cholesterol; 49.0 versus 55.0 mg/dL), and higher triglycerides (143 versus 114 mg/dL), LDL-C (low-density lipoprotein cholesterol; 133 versus 124 mg/dL), and lipoprotein insulin resistance score (52.6 versus 37.3; all: P<0.0001). Similar associations with these biomarkers were observed in isoleucine, leucine, and valine, respectively. CONCLUSIONS: Higher circulating BCAA concentrations are associated with adverse profiles of biomarkers of inflammation and dyslipidemia independent of established cardiovascular disease risk factors, and thus, may reflect poorer cardiometabolic health through multiple pathways. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00000479.
BACKGROUND: Branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) correlate with insulin resistance and poor glucose control, which may in part explain associations between type 2 diabetes and cardiovascular disease. However, the relationships of BCAAs with other cardiometabolic pathways, including inflammation and dyslipidemia, are unclear. We hypothesized that plasma BCAAs would correlate with multiple pathways of cardiometabolic dysfunction. METHODS: We conducted a cross-sectional analysis among 19 472 participants (mean age=54.9 years, SD=7.2 years) in the Women's Health Study without a history of type 2 diabetes, cardiovascular disease, or cancer. We quantified the concentrations of individual biomarkers of inflammation and lipids, across quartiles of BCAAs, adjusting for age, smoking, body mass index, physical activity, and other established cardiovascular disease risk factors at blood draw. RESULTS: Women in the highest versus lowest quartiles of plasma BCAAs had higher inflammatory markers including high-sensitivity C-reactive protein (multivariable-adjusted means: 1.96 versus 1.43 mg/L), fibrinogen (367 versus 362 mg/dL), soluble intercellular cell adhesion molecule-1 (361 versus 353 ng/mL), and glycoprotein acetylation (407 versus 371 µmol/L; P trend=0.0002 for fibrinogen; P<0.0001 for others). Similarly for lipids, women with higher BCAAs had lower HDL-C (high-density lipoprotein cholesterol; 49.0 versus 55.0 mg/dL), and higher triglycerides (143 versus 114 mg/dL), LDL-C (low-density lipoprotein cholesterol; 133 versus 124 mg/dL), and lipoprotein insulin resistance score (52.6 versus 37.3; all: P<0.0001). Similar associations with these biomarkers were observed in isoleucine, leucine, and valine, respectively. CONCLUSIONS: Higher circulating BCAA concentrations are associated with adverse profiles of biomarkers of inflammation and dyslipidemia independent of established cardiovascular disease risk factors, and thus, may reflect poorer cardiometabolic health through multiple pathways. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00000479.
Authors: Akintunde O Akinkuolie; Aruna D Pradhan; Julie E Buring; Paul M Ridker; Samia Mora Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: Mirjam A Lips; Jan B Van Klinken; Vanessa van Harmelen; Harish K Dharuri; Peter A C 't Hoen; Jeroen F J Laros; Gert-Jan van Ommen; Ignace M Janssen; Bert Van Ramshorst; Bart A Van Wagensveld; Dingeman J Swank; Francois Van Dielen; Adrie Dane; Amy Harms; Rob Vreeken; Thomas Hankemeier; Johannes W A Smit; Hanno Pijl; Ko Willems van Dijk Journal: Diabetes Care Date: 2014-10-14 Impact factor: 19.112
Authors: Yan Zheng; Uta Ceglarek; Tao Huang; Lerong Li; Jennifer Rood; Donna H Ryan; George A Bray; Frank M Sacks; Dan Schwarzfuchs; Joachim Thiery; Iris Shai; Lu Qi Journal: Am J Clin Nutr Date: 2016-01-20 Impact factor: 7.045
Authors: Jared R Mayers; Chen Wu; Clary B Clish; Peter Kraft; Margaret E Torrence; Brian P Fiske; Chen Yuan; Ying Bao; Mary K Townsend; Shelley S Tworoger; Shawn M Davidson; Thales Papagiannakopoulos; Annan Yang; Talya L Dayton; Shuji Ogino; Meir J Stampfer; Edward L Giovannucci; Zhi Rong Qian; Douglas A Rubinson; Jing Ma; Howard D Sesso; John Michael Gaziano; Barbara B Cochrane; Simin Liu; Jean Wactawski-Wende; JoAnn E Manson; Michael N Pollak; Alec C Kimmelman; Amanda Souza; Kerry Pierce; Thomas J Wang; Robert E Gerszten; Charles S Fuchs; Matthew G Vander Heiden; Brian M Wolpin Journal: Nat Med Date: 2014-09-28 Impact factor: 53.440
Authors: Sagar B Dugani; M Vinayaga Moorthy; Chunying Li; Olga V Demler; Alawi A Alsheikh-Ali; Paul M Ridker; Robert J Glynn; Samia Mora Journal: JAMA Cardiol Date: 2021-04-01 Impact factor: 30.154
Authors: Rikuta Hamaya; Samia Mora; Patrick R Lawler; Nancy R Cook; Julie E Buring; I-Min Lee; JoAnn E Manson; Deirdre K Tobias Journal: J Nutr Date: 2022-06-09 Impact factor: 4.687